A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19
Coronavirus disease 2019 (COVID-19) is a severe acute respiratory disease with a high prevalence. According to the research and statistical data, in January 2021, there have been 92,262,621 confirmed cases of COVID-19 and more than two million deaths. Infection with the severe acute respiratory synd...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Golestan University Of Medical Sciences
2022-02-01
|
| Series: | Journal of Clinical and Basic Research |
| Subjects: | |
| Online Access: | http://jcbr.goums.ac.ir/article-1-324-en.html |
| _version_ | 1828084251473477632 |
|---|---|
| author | Fatemeh EmamiPari Soroush Kamali Ghazaleh Nikzad Narges Roosta Navi Sanaz Soltani Mohamad Reza Kalani |
| author_facet | Fatemeh EmamiPari Soroush Kamali Ghazaleh Nikzad Narges Roosta Navi Sanaz Soltani Mohamad Reza Kalani |
| author_sort | Fatemeh EmamiPari |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) is a severe acute respiratory disease with a high prevalence. According to the research and statistical data, in January 2021, there have been 92,262,621 confirmed cases of COVID-19 and more than two million deaths. Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of this disease. In addition to the respiratory system, the disease affects the gastrointestinal tract, central-peripheral nervous system, circulatory system, and kidneys. Therefore, any therapeutic action to reduce COVID-19-related symptoms and complications is essential. In this study, we conducted a systematic review of the published literature and preprints on the efficacy of erythropoietin (EPO) and recombinant human EPO as a safe stimulant and tissue protector in the treatment of COVID-19. We also briefly described the structure of coronavirus, its pathogenesis, and the structure of EPO and recombinant human EPO. All relevant articles published in the Science Direct, PubMed, and Google Scholar databases were searched. According to the results, EPO is a cytoprotective cytokine induced by hypoxia. The pleiotropic effects of EPO are associated with its erythrocyte-forming, anti-apoptotic, anti-inflammatory activities. It also exerts protective effects on the heart, lungs, kidneys, arteries, and central and peripheral nervous systems. It has been demonstrated that EPO can increase hemoglobin levels, thereby increasing oxygen delivery to the tissues. Therefore, recombinant human EPO therapy can be used for counteracting the adverse effects of COVID-19 including hypoxic myocarditis, acute renal failure, pulmonary edema, and brain-spinal cord ischemic injury. Overall, the use of EPO and recombinant human EPO therapy increases blood coagulation, tumor growth, thromboembolism, and purification of red blood cells, which must be accompanied by anticoagulants such as heparin. |
| first_indexed | 2024-04-11T04:21:06Z |
| format | Article |
| id | doaj.art-dccdad05bd384d659434f9e94e16970d |
| institution | Directory Open Access Journal |
| issn | 2538-3736 |
| language | English |
| last_indexed | 2024-04-11T04:21:06Z |
| publishDate | 2022-02-01 |
| publisher | Golestan University Of Medical Sciences |
| record_format | Article |
| series | Journal of Clinical and Basic Research |
| spelling | doaj.art-dccdad05bd384d659434f9e94e16970d2022-12-30T17:26:13ZengGolestan University Of Medical SciencesJournal of Clinical and Basic Research2538-37362022-02-01611127A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19Fatemeh EmamiPari0Soroush Kamali1Ghazaleh Nikzad2Narges Roosta Navi3Sanaz Soltani4Mohamad Reza Kalani5 Department of Animal Sciences, College of Life Sciences, Kharazmi University of Tehran, Tehran, Iran Department of Molecular Cell Biology - Molecular Cell Science, Faculty of Basic Sciences, Mohaghegh Ardabili University, Ardabil, Iran Department of Molecular Cell Biology - Molecular Cell Science, Faculty of Basic Sciences, Mohaghegh Ardabili University, Ardabil, Iran Department of Molecular Cell Biology - Molecular Cell Science, Payame Noor University of Talesh, Gilan, Iran Department of Biology, Shahr-e-Quds Branch, Islamic Azad University, Tehran, Iran Molecular Medicine Department, Golestan University of Medical Sciences, Gorgan, Iran Coronavirus disease 2019 (COVID-19) is a severe acute respiratory disease with a high prevalence. According to the research and statistical data, in January 2021, there have been 92,262,621 confirmed cases of COVID-19 and more than two million deaths. Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of this disease. In addition to the respiratory system, the disease affects the gastrointestinal tract, central-peripheral nervous system, circulatory system, and kidneys. Therefore, any therapeutic action to reduce COVID-19-related symptoms and complications is essential. In this study, we conducted a systematic review of the published literature and preprints on the efficacy of erythropoietin (EPO) and recombinant human EPO as a safe stimulant and tissue protector in the treatment of COVID-19. We also briefly described the structure of coronavirus, its pathogenesis, and the structure of EPO and recombinant human EPO. All relevant articles published in the Science Direct, PubMed, and Google Scholar databases were searched. According to the results, EPO is a cytoprotective cytokine induced by hypoxia. The pleiotropic effects of EPO are associated with its erythrocyte-forming, anti-apoptotic, anti-inflammatory activities. It also exerts protective effects on the heart, lungs, kidneys, arteries, and central and peripheral nervous systems. It has been demonstrated that EPO can increase hemoglobin levels, thereby increasing oxygen delivery to the tissues. Therefore, recombinant human EPO therapy can be used for counteracting the adverse effects of COVID-19 including hypoxic myocarditis, acute renal failure, pulmonary edema, and brain-spinal cord ischemic injury. Overall, the use of EPO and recombinant human EPO therapy increases blood coagulation, tumor growth, thromboembolism, and purification of red blood cells, which must be accompanied by anticoagulants such as heparin.http://jcbr.goums.ac.ir/article-1-324-en.htmlerythropoietincovid-19hypoxiarecombinant human erythropoietinpleiotropic |
| spellingShingle | Fatemeh EmamiPari Soroush Kamali Ghazaleh Nikzad Narges Roosta Navi Sanaz Soltani Mohamad Reza Kalani A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19 Journal of Clinical and Basic Research erythropoietin covid-19 hypoxia recombinant human erythropoietin pleiotropic |
| title | A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19 |
| title_full | A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19 |
| title_fullStr | A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19 |
| title_full_unstemmed | A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19 |
| title_short | A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19 |
| title_sort | review of pleiotropic potential of erythropoietin as an adjunctive therapy for covid 19 |
| topic | erythropoietin covid-19 hypoxia recombinant human erythropoietin pleiotropic |
| url | http://jcbr.goums.ac.ir/article-1-324-en.html |
| work_keys_str_mv | AT fatemehemamipari areviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT soroushkamali areviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT ghazalehnikzad areviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT nargesroostanavi areviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT sanazsoltani areviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT mohamadrezakalani areviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT fatemehemamipari reviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT soroushkamali reviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT ghazalehnikzad reviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT nargesroostanavi reviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT sanazsoltani reviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 AT mohamadrezakalani reviewofpleiotropicpotentialoferythropoietinasanadjunctivetherapyforcovid19 |